Literature DB >> 8548527

Clinical utility of complement assessment.

A E Ahmed1, J B Peter.   

Abstract

Mesh：

Substances：

Year:  1995        PMID： 8548527      PMCID： PMC170192          DOI： 10.1128/cdli.2.5.509-517.1995

Source DB:  PubMed          Journal:  Clin Diagn Lab Immunol        ISSN： 1071-412X


× No keyword cloud information.
  81 in total

Review 1.  The complement profile in clinical medicine. Inherited and acquired conditions lowering the serum concentrations of complement component and control proteins.

Authors:  C D West
Journal:  Complement Inflamm       Date:  1989

Review 2.  Control of immune complexes by the classical pathway.

Authors:  K Whaley; A E Ahmed
Journal:  Behring Inst Mitt       Date:  1989-07

3.  Factor B activation products in patients with systemic lupus erythematosus. A marker of severe disease activity.

Authors:  L D Kerr; B R Adelsberg; P Schulman; H Spiera
Journal:  Arthritis Rheum       Date:  1989-11

4.  Nafamostat to stabilise plasma samples taken for complement measurements.

Authors:  J Watkins; G Wild; S Smith
Journal:  Lancet       Date:  1989-04-22       Impact factor: 79.321

5.  Roles of histamine, complement and xanthine oxidase in thermal injury of skin.

Authors:  H P Friedl; G O Till; O Trentz; P A Ward
Journal:  Am J Pathol       Date:  1989-07       Impact factor: 4.307

6.  Quantitation of the anaphylatoxin C3a in the presence of C3 by a novel sandwich ELISA using monoclonal antibody to a C3a neoepitope.

Authors:  G Zilow; W Naser; R Rutz; R Burger
Journal:  J Immunol Methods       Date:  1989-07-26       Impact factor: 2.303

7.  A new method for the estimation of C3d. Affinity clearance of C-determinant-bearing C3 molecules and fragments followed by estimation of C3d by ELISA.

Authors:  S S Asghar; B Schraag; A H Backhaus; I Zorn; G T Venneker; A J Hannema
Journal:  J Immunol Methods       Date:  1989-06-21       Impact factor: 2.303

Review 8.  Ba and Bb fragments of factor B activation: fragment production, biological activities, neoepitope expression and quantitation in clinical samples.

Authors:  W P Kolb; P R Morrow; J D Tamerius
Journal:  Complement Inflamm       Date:  1989

9.  The clinical significance of iC3b neoantigen expression in plasma from patients with systemic lupus erythematosus.

Authors:  N Negoro; M Okamura; T Takeda; S Koda; K Amatsu; T Inoue; J G Curd; Y Kanayama
Journal:  Arthritis Rheum       Date:  1989-10

10.  Complement receptors and regulatory proteins in human atherosclerotic lesions.

Authors:  P S Seifert; G K Hansson
Journal:  Arteriosclerosis       Date:  1989 Nov-Dec
View more
  5 in total

1.  Acquisition of factor H by a novel surface protein on group B Streptococcus promotes complement degradation.

Authors:  Ravi Maruvada; Nemani V Prasadarao; C E Rubens
Journal:  FASEB J       Date:  2009-07-16       Impact factor: 5.191

2.  Evidence for complement activation in the amniotic fluid of women with spontaneous preterm labor and intra-amniotic infection.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Bo H Yoon; Tinnakorn Chaiworapongsa; Edi Vaisbuch; Pooja Mittal; Offer Erez; Francesca Gotsch; Moshe Mazor; Juan P Kusanovic
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

3.  Anaphylatoxins in preterm and term labor.

Authors:  Eleazar Soto; Roberto Romero; Karina Richani; Jimmy Espinoza; Jyh Kae Nien; Tinnakorn Chaiworapongsa; Joaquin Santolaya-Forgas; Samuel S Edwin; Moshe Mazor
Journal:  J Perinat Med       Date:  2005       Impact factor: 1.901

4.  Normal pregnancy is characterized by systemic activation of the complement system.

Authors:  Karina Richani; Eleazar Soto; Roberto Romero; Jimmy Espinoza; Tinnakorn Chaiworapongsa; Jyh Kae Nien; Samuel Edwin; Yeon Mee Kim; Joon-Seok Hong; Moshe Mazor
Journal:  J Matern Fetal Neonatal Med       Date:  2005-04

5.  Altered Toll-Like Receptor-4 Response to Lipopolysaccharides in Infants Exposed to HIV-1 and Its Preventive Therapy.

Authors:  Anicet Christel Maloupazoa Siawaya; Ofilia Mvoundza Ndjindji; Eliane Kuissi Kamgaing; Amandine Mveang-Nzoghe; Chérone Nancy Mbani Mpega; Marielle Leboueny; Roselyne Kengue Boussougou; Armel Mintsa Ndong; Paulin N Essone; Joel Fleury Djoba Siawaya
Journal:  Front Immunol       Date:  2018-02-14       Impact factor: 7.561
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.